Takuya Sadahira

Dr. Takuya Sadahira

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2017 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
YMYosuke Mitsui
Yosuke Mitsui
TSTakuya Sadahira
Takuya Sadahira
MAMotoo Araki
Motoo Araki
KWKoichiro Wada
Koichiro Wada
RTRyuta Tanimoto
Ryuta Tanimoto
YNYasutomo Nasu
Yasutomo Nasu

18 May 2023 in Frontiers in Microbiology
Verified
Journal Article
Open access
TSTakanori Sekito
Takanori Sekito
KWKoichiro Wada
Koichiro Wada
AIAyano Ishii
Ayano Ishii
TITakehiro Iwata
Takehiro Iwata
TMTakehiro Matsubara
Takehiro Matsubara
TSTakuya Sadahira
Takuya Sadahira
Background: The vaginal microbiota can be altered by uropathogenic bacteria associated with recurrent cystitis (RC), and the vaginal administration of Lactobacillus have suggested certain effects to prevent RC. The relationship between vaginal microbiota and the development of RC has not been elucidated. We aimed to clarify the etiology of RC from vaginal microbiota and importance of vaginal Lactobacillus.Methods: Vaginal samples obtained from 39 postmenopausal women were classified into four groups: healthy controls; uncomplicated cystitis; RC; and prevention (prevented RC by Lactobacillus crispatus-containing vaginal suppositories). Principal coordinate analysis and beta-diversity analysis was used to assess 16S rRNA gene sequencing data from the vaginal microbiome.Results: Cluster analysis divided the vaginal bacterial communities among 129 vaginal samples into three clusters (A, B, and C). Fourteen of 14 (100%) samples from the RC group and 51 of 53 (96%) samples from the prevention group were in clusters B and C, while 29 of 38 (76%) samples from the healthy group and 14 of 24 (58%) samples from the uncomplicated cystitis group were in cluster A. The principal coordinate analysis showed that plots in the uncomplicated cystitis group were similar to the healthy group, indicating a large separation between the RC group and the uncomplicated cystitis group. On beta-diversity analysis, there were significant differences between the healthy group and the uncomplicated cystitis group (p = 0.045), and between the RC group and the uncomplicated cystitis group or the healthy group (p = 0.001, p = 0.001, respectively). There were no significant differences between the RC group and the prevention group (p = 0.446). The top six taxa were as follows: Prevotella, Lactobacillus, Streptococcus, Enterobacteriaceae, Anaerococcus, and Bifidobacterium. Among patients with RC, Lactobacillus was undetectable before administration of suppositories, while the median relative abundance of Lactobacillus was 19% during administration of suppositories (p = 0.0211), reducing the average cystitis episodes per year (6.3 vs. 2.4, p = 0.0015).Conclusion: The vaginal microbiota of postmenopausal women with RC is differed from healthy controls and uncomplicated cystitis in terms of lack of Lactobacillus and relatively dominant of Enterobacteriaceae. Vaginal administration of Lactobacillus-containing suppositories can prevent RC by stabilizing vaginal dysbiosis and causing a loss of pathogenic bacteria virulence.

26 April 2018 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
YMYuki Maruyama
Yuki Maruyama
TSTakuya Sadahira
Takuya Sadahira
YMYosuke Mitsui
Yosuke Mitsui
MAMotoo Araki
Motoo Araki
KWKoichiro Wada
Koichiro Wada
YNYasutomo Nasu
Yasutomo Nasu

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
NXNaijin Xu
Naijin Xu
WLWenfeng Lin
Wenfeng Lin
JSJingkai Sun
Jingkai Sun
TSTakuya Sadahira
Takuya Sadahira
AXAbai Xu
Abai Xu
PHPeng HUANG
Peng HUANG
Nitroxoline is considered to be an effective treatment for the urinary tract infections. Recently, it has been found to be effective against several cancers. However, few studies have examined the anti-tumor activity of nitroxoline in bladder cancer. The purpose of the study was to reveal the possible mechanisms how nitroxoline inhibited bladder cancer progression. In vitro assay, we demonstrated that nitroxoline inhibited bladder cancer cell growth and migration in a concentration-related manner. Western blot analysis demonstrated that nitroxoline downregulated the expressions of epithelial mesenchymal transition (EMT)-related proteins. Furthermore, treatment with nitroxoline in the C3H/He mice bladder cancer subcutaneous model resulted in significant inhibition of tumor growth. Moreover, the percentage of myeloid‐derived suppressor cells (MDSC) in peripheral blood cells significantly decreased after treatment of nitroxoline. Taken together, our results suggested that nitroxoline may be used as a potential drug for bladder cancer.

1 March 2019 in Urology
Verified
Journal Article
Closed access
YMYosuke Mitsui
Yosuke Mitsui
TSTakuya Sadahira
Takuya Sadahira
MAMotoo Araki
Motoo Araki
YMYuki Maruyama
Yuki Maruyama
SNShingo Nishimura
Shingo Nishimura
YNYasutomo Nasu
Yasutomo Nasu

8 April 2019 in Molecular and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YTYusuke Tominaga
Yusuke Tominaga
TSTakuya Sadahira
Takuya Sadahira
YMYosuke Mitsui
Yosuke Mitsui
YMYuki Maruyama
Yuki Maruyama
RTRyuta Tanimoto
Ryuta Tanimoto
SHShunji Hayata
Shunji Hayata
The aim of the present study was to investigate the impact of incidental prostate cancer (IPCa), which was diagnosed by holmium laser enucleation of the prostate (HoLEP), on long‑term oncological and functional outcomes. A total of 482 patients who underwent HoLEP for benign prostatic hyperplasia (BPH) between 2008 and 2016 at our institution were retrospectively reviewed. We defined IPCa as prostate cancer (PCa) according to the enucleated tissue of transitional zone. Therefore, 64 patients were excluded for the following reasons: Prostate‑specific antigen (PSA) ≥4.0 ng/ml and no prostate biopsy (n=46); and PSA ≥4.0 ng/ml and diagnosed with PCa by prostate biopsy performed during HoLEP (n=18). Notably, 418 patients were included in the study and divided into two groups: The BPH group and the IPCa group. For 5 years, postoperative PSA and functional outcomes were evaluated. Of 418 patients, 25 (6%) were diagnosed with IPCa by HoLEP, 21 patients (84%) had a Gleason score ≤6 and 5 patients (20%) received adjuvant therapy for PCa following HoLEP. No significant differences were observed between groups for preoperative PSA, PSA density, or urinary and sexual function outcomes; however, age at the time of HoLEP significantly differed between groups (71.7 vs. 75.5 years, P=0.026). Long‑term (5‑year) urinary outcomes demonstrated sustained improvement. Postoperative PSA increased gradually in the IPCa group (3‑year, P=0.033; 4‑year, P=0.037); International Index of Erectile Function 5 conversely decreased (5‑year, P=0.068). According to the present results, if standard PSA screening and prostate biopsy are performed, watchful waiting for IPCa is feasible, and IPCa does not impact on 5‑year urinary outcomes.